Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03674411
Other study ID # 2018LS051
Secondary ID MT2018-06
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date January 2, 2019
Est. completion date June 28, 2024

Study information

Verified date March 2024
Source Masonic Cancer Center, University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L, IL-6 and thromopoietin) on lympho-hematopoietic recovery. Patients will receive a uniform myeloablative conditioning and post-transplant immunoprophylaxis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 22
Est. completion date June 28, 2024
Est. primary completion date June 23, 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 55 Years
Eligibility Age, Unit Cell Dose and HLA Match Criteria - Subjects must be =55 years of age - Subjects must weigh >11 kg - Subjects must have a partially HLA matched UCB unit with a pre-cryopreserved TNC dose >1.0 x 107 per kilogram recipient weight. HLA matching is initially based on a minimum of 5 of 8 HLA alleles at high resolution A, B, C, DRB1 typing; searches will be performed according to the current Magenta Cord Blood Search Algorithm. Eligible Diseases: - Acute myelogenous leukemia (AML) in morphological complete remission with: - Minimal residual disease (MRD) by flow cytometry, or - Intermediate to high risk leukemia in first (CR1) based on institutional criteria, eg. not favorable risk AML which is defined as having one of the following: - t(8,21) without cKIT mutation - inv(16) or t(16;16) without cKIT mutation - Normal karyotype with mutated NPM1 but FLT3-ITD wild type - Normal karyotype with double mutated CEBPA - Acute promyelocytic leukemia (APL) in first molecular remission at the end of consolidation - Any second or subsequent CR, or - Secondary AML with prior malignancy that has been in remission for at least 12 months. - Acute lymphocytic leukemia (ALL) at the following stages: - High risk first morphological, cytogenetic and molecular CR with: - MRD by flow cytometry, or - Diagnosis of Philadelphia chromosome (Ph)+ ALL, or - MLL rearrangement at diagnosis with slow early response at Day 14, or - Hypodiploidy (< 44 chromosomes or DNA index < 0.81) at diagnosis, or - End of induction M3 bone marrow, or - End of induction M2 with M2-3 at Day 42. - High risk second CR based on institutional criteria (eg, for children, bone marrow relapse <36 months from induction or T-lineage bone marrow relapse or very early isolated central nervous system (CNS) relapse <6 months from diagnosis, or slow re-induction (stage M2-3 at day 28 after induction) regardless of length remission. All patients with MRD by flow cytometry. - Any third or subsequent CR. - Secondary ALL - Biphenotypic/undifferentiated leukemia in morphological, cytogenetic and molecular CR . - Chronic Myelogenous Leukemia (CML) in high risk first chronic phase (failure of two tyrosine kinase inhibitors (TKI) or TKI intolerance), accelerated phase or second chronic phase. - Myelodysplasia (MDS) IPSS Int-2 or High risk (i.e. RAEB, RAEBt <5% blasts) or other high risk features, including multiple cytopenias, high risk cytogenetics or lack of response to standard therapy.. - Relapsed large-cell lymphoma, mantle-cell lymphoma and Hodgkin lymphoma that is chemotherapy sensitive and ineligible for an autologous transplant. - Burkitt's lymphoma in CR2 or subsequent CR. - Relapsed T-cell lymphoma that is chemotherapy sensitive in CR/PR that is ineligible for an autologous transplant. Organ Specific Inclusion Criteria - Karnofsky score =70 (16 years and older), Lansky play score >50 (children 2-16 years, or 'adequate' score for children <2 years, as detailed in Appendix II. - Adequate organ function defined as: - Renal: Serum creatinine within normal range for age, or if serum creatinine outside normal range for age, then creatinine clearance >40 ml/min or GFR =70 mL/min/1.73 m2.normal for age - Hepatic: Bilirubin <3x upper limit of normal (ULN) and AST, ALT and alkaline phosphatase <5x ULN. - Pulmonary function: DLCO, FEV1, FEC (diffusion capacity) >5030% of predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, then O2 saturation >95% on room air. - Cardiac: No uncontrolled arrhythmia and left ventricular ejection fraction at rest must be >3545%. - Available 'back-up' HSPC graft (e.g, second UCB unit, haploidentical related donor). - Females of child bearing potential and sexually active males must agree to use adequate birth control during study treatment. - Voluntary written consent signed (adult or parental) before performance of any study-related procedure not part of normal medical care. Exclusion Criteria - Patients with a HLA matched sibling donor or a HLA matched unrelated donor who is available for marrow or peripheral blood stem cell collection at the desired time of transplant. - Pregnant or breast feeding. The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. Females of childbearing potential must have a blood test or urine study within 14 days prior to study enrollment to rule out pregnancy. - Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology. - Active bacterial, viral or fungal infection (currently taking medication and persistence of clinical signs and symptoms) with a minimum of 4 weeks of anti-fungal treatment - Prior autologous or allogeneic transplant. - Other active malignancy. - Subjects >2 3 years of age unable to receive TBI 1320 cGy due to extensive prior therapy including >12 months alkylator therapy or >6 months alkylator therapy with extensive radiation, or prior Y-90 ibritumomab (Zevalin) or I-131 tostumomab (Bexxar), as part of their salvage therapy.

Study Design


Intervention

Drug:
Fludarabine (FLU)
25 mg/m2 IV over 1 hour (<10 kg: 0.83 mg/kg IV over 1 hour)
Cyclophosphamide (CY)
60 mg/kg IV over 2 hours
Total Body Irradiation (TBI)
165 cGy twice daily
Tacrolimus (Tac)
Tacrolimus will start day -3 and will be administered as a continuous IV infusion at a starting dose of 0.03 mg/kg/day. Goal trough levels will be 10-15 ng/mL for the first 14 days post-transplant and then decreased to a goal of 5-10 ng/ml thereafter.
Mycophenolate Mofetil (MMF)
MMF 3 gram/day IV/PO for adult patients divided in 2 or 3 doses. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (max 1 gram per dose) every 8 hours beginning day -3.
Granulocyte Colony-Stimulating Factor (G-CSF)
5 ug/kg/d until the absolute neutrophil count (ANC) is >2500/uL for 2 consecutive days
Busulfan (BU)
BU IV once daily with dose based on Pharmacokinetics (PK) calculator over 3 hours
Melphalan
50 mg/m2/day (1.7 mg/kg/day if < 10 kg) IV over 30 min
MGTA 456 Infusion
The target cell dose is >10 x 106 CD34/kg with a maximum TNC 2.7 x 108/kg for children (<18 years) and 8.1 × 108 cells/kg [expanded product only] for adults based on the highest cell dose windows evaluated in prior studies.

Locations

Country Name City State
United States Masonic Cancer Center at University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Neutrophil Recover Percentage of participants with neutrophil recovery by day 14 after transplantation in recipients of MGTA-456. Day 14
Secondary Hospitalization Rates Number of days alive without hospitalization between days 0 and 100 after transplantation Day 0 and Day 100
Secondary Secondary Graft Failure Incidence of secondary graft failure 2 Years
Secondary Platelet Recovery Incidence of platelet recovery at day 42 Day 42
Secondary Treatment Related Mortality (TRM) Incidence of TRM at 6 months 6 Months
Secondary Grades II-IV Acute GVHD Incidence of grades II-IV acute GVHD at day 100 Day 100
Secondary Grades III-IV Acute GVHD Incidence of grades III-IV acute GVHD at day 100 Day 100
Secondary Chronic GVHD Incidence of chronic GVHD at 1 year 1 Year
Secondary Relapse Incidence of relapse at 2 years 2 Years
Secondary Non-catheter Associated Bacterial Infections Incidence of non-catheter associated bacterial infections by day 100 Day 100
Secondary Overall Survival (OS) Incidence of overall survival (OS) at 2 years 2 Years
Secondary Event-Free Survival (EFS) Incidence of event-free survival (EFS) at 2 years 2 Years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2